Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 355

1.

Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.

Chu H, Zhong C, Xue G, Liang X, Wang J, Liu Y, Zhao S, Zhou Q, Bi J.

Oncol Rep. 2013 Nov;30(5):2311-5. doi: 10.3892/or.2013.2709.

PMID:
24002698
3.

Comparison of ARMS and direct sequencing for detection of EGFR mutation and prediction of EGFR-TKI efficacy between surgery and biopsy tumor tissues in NSCLC patients.

Shaozhang Z, Ming Z, Haiyan P, Aiping Z, Qitao Y, Xiangqun S.

Med Oncol. 2014 May;31(5):926. doi: 10.1007/s12032-014-0926-3.

PMID:
24748405
4.

Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.

Kim HJ, Lee KY, Kim YC, Kim KS, Lee SY, Jang TW, Lee MK, Shin KC, Lee GH, Lee JC, Lee JE, Kim SY.

Lung Cancer. 2012 Mar;75(3):321-5. doi: 10.1016/j.lungcan.2011.08.005.

PMID:
21930325
5.

EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.

Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K, Nishio K.

Br J Cancer. 2006 Nov 20;95(10):1390-5.

6.

Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing.

Yeo CD, Kim JW, Kim KH, Ha JH, Rhee CK, Kim SJ, Kim YK, Park CK, Lee SH, Park MS, Yim HW.

Lung Cancer. 2013 Aug;81(2):207-12. doi: 10.1016/j.lungcan.2013.04.023.

PMID:
23726527
7.

High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients.

Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K, Nishio K.

Cancer Sci. 2006 Jul;97(7):642-8.

8.

[A comparison of direct sequencing and ARMS assay performance in EGFR mutation analysis of non-small cell lung cancer patients].

Li C, Wu J, Wang Z, Feng J.

Zhongguo Fei Ai Za Zhi. 2014 Aug 20;17(8):606-11. doi: 10.3779/j.issn.1009-3419.2014.08.05. Chinese.

9.

Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes.

Lozano MD, Zulueta JJ, Echeveste JI, Gúrpide A, Seijo LM, Martín-Algarra S, Del Barrio A, Pio R, Idoate MA, Labiano T, Perez-Gracia JL.

Oncologist. 2011;16(6):877-85. doi: 10.1634/theoncologist.2010-0155.

10.

[Detection of epidermal growth factor receptor mutations in non-small cell lung cancer by real-time PCR using TaqMan-MGB probes].

Zhou CC, Zhou SW, Pan H, Su B, Gao ZQ.

Zhonghua Zhong Liu Za Zhi. 2007 Feb;29(2):119-23. Chinese.

PMID:
17645848
11.
12.

RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.

Tsai TH, Su KY, Wu SG, Chang YL, Luo SC, Jan IS, Yu CJ, Yu SL, Shih JY, Yang PC.

Eur Respir J. 2012 Mar;39(3):677-84. doi: 10.1183/09031936.00043511.

13.

Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.

Kawahara A, Azuma K, Sumi A, Taira T, Nakashima K, Aikawa E, Abe H, Yamaguchi T, Takamori S, Akiba J, Kage M.

Lung Cancer. 2011 Oct;74(1):35-40. doi: 10.1016/j.lungcan.2011.02.002.

PMID:
21444121
14.

Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.

Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, Yang XN, An SJ, Wang BC, Huang YS, Wang Z, Wu YL.

J Clin Oncol. 2011 Aug 20;29(24):3316-21. doi: 10.1200/JCO.2010.33.3757.

PMID:
21788562
15.
16.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.

J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Erratum in: J Clin Oncol. 2008 Jul 10;26(20):3472.

PMID:
18458038
17.

[Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types].

Sun MH, Yang F, Shen L, Zhang L, Chen Y, Cai X, Zhu XL, Zhou XY.

Zhonghua Bing Li Xue Za Zhi. 2011 Oct;40(10):655-9. Chinese.

PMID:
22321541
18.

Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer.

Horiike A, Kimura H, Nishio K, Ohyanagi F, Satoh Y, Okumura S, Ishikawa Y, Nakagawa K, Horai T, Nishio M.

Chest. 2007 Jun;131(6):1628-34.

PMID:
17565015
19.

The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies.

Liu X, Lu Y, Zhu G, Lei Y, Zheng L, Qin H, Tang C, Ellison G, McCormack R, Ji Q.

J Clin Pathol. 2013 Dec;66(12):1065-9. doi: 10.1136/jclinpath-2013-201728.

20.

Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.

Peters MJ, Bowden JJ, Carpenter P, Lewis J, Solomon B.

Intern Med J. 2014 Jun;44(6):575-80. doi: 10.1111/imj.12449.

PMID:
24720523
Items per page

Supplemental Content

Support Center